EU Grants Full Approval to Osimertinib for EGFR T790M-Positive NSCLC

April 26, 2017 – The European Union (EU) has granted a full approval to osimertinib for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive non–small cell lung cancer (NSCLC), regardless of prior treatment with an EGFR TKI. This full approval comes a bit more than a year after osimertinib became the new first medicine to win clearance under the European Commission’s expedited process. The FDA in March awarded … (leggi tutto)